The majority of non–small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. Unfortunately, a subset of patients with EGFR mutations are refractory to EGFR-TKIs. Resistance to EGFR inhibitors reportedly involves SRC activation and induction of epithelial-to-mesenchymal transition (EMT). Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI–sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. Furthermore, tumors from NSCLC patients with EGFR-activating mutations that were intrinsically resistant to EGFR-TKIs expressed higher levels of CRIPTO1 compared with tumors from patients that were sensitive to EGFR-TKIs. Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. CRIPTO1 activated SRC and ZEB1 to promote EMT via microRNA-205 (miR-205) downregulation. While miR-205 depletion induced erlotinib resistance, miR-205 overexpression inhibited CRIPTO1-dependent ZEB1 and SRC activation, restoring erlotinib sensitivity. CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC.
Kang-Seo Park, Mark Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Bianco, Trung Pham, Liam C. Lee, Tetsuya Mitsudomi, Yasushi Yatabe, Isamu Okamoto, Deepa Subramaniam, Tony Mok, Rafael Rosell, Ji Luo, David S. Salomon, Yisong Wang, Giuseppe Giaccone
Title and authors | Publication | Year |
---|---|---|
DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma
Fan W, Xing Y, Yan S, Liu W, Ning J, Tian F, Wang X, Zhan Y, Luo L, Cao M, Huang J, Cai L |
Cancer Cell International | 2024 |
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
Masciale V, Banchelli F, Grisendi G, Samarelli AV, Raineri G, Rossi T, Zanoni M, Cortesi M, Bandini S, Ulivi P, Martinelli G, Stella F, Dominici M, Aramini B |
The Journal of Biological Chemistry | 2024 |
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M, Fedele P |
Pharmaceutics | 2023 |
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Calabrese F, Pezzuto F, Lunardi F, Fortarezza F, Tzorakoleftheraki SE, Resi MV, Tiné M, Pasello G, Hofman P |
International journal of molecular sciences | 2022 |
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJ, Huang YH, Chang GC |
Scientific Reports | 2022 |
CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer
Francescangeli F, De Angelis ML, Rossi R, Sette G, Eramo A, Boe A, Guardiola O, Tang T, Yu SC, Minchiotti G, Zeuner A |
Frontiers in Oncology | 2022 |
Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer
Luo L, Yao X, Xiang J |
Oxidative medicine and cellular longevity | 2022 |
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy
H Ishii, SM Afify, G Hassan, DS Salomon, M Seno |
Cancers | 2021 |
Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal
DW Freeman, ER Sousa, S Karkampouna, E Zoni, PC Gray, DS Salomon, MK Julio, BT Spike |
International journal of molecular sciences | 2021 |
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
G Pan, Y Liu, L Shang, F Zhou, S Yang |
2021 | |
Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models
S Gómez-López, ZE Whiteman, SM Janes |
2021 | |
Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
R Pathak, VM Villaflor |
Cancers | 2021 |
A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
C Kim, SV Liu, J Crawford, T Torres, V Chen, J Thompson, M Tan, G Esposito, DS Subramaniam, G Giaccone |
Frontiers in Oncology | 2021 |
Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer
Y Zhang, K Mi, Z Li, L Qiang, M Lv, Y Wu, L Yuan, S Jin |
Frontiers in Oncology | 2021 |
A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles
ER Sousa, E Zoni, S Karkampouna, FL Manna, PC Gray, MD Menna, MK Julio |
Cancers | 2020 |
Conditional reprogramming: next generation cell culture
X Wu, S Wang, M Li, J Li, J Shen, Y Zhao, J Pang, Q Wen, M Chen, B Wei, PJ Kaboli, F Du, Q Zhao, CH Cho, Y Wang, Z Xiao, X Wu |
Acta pharmaceutica Sinica. B | 2020 |
Structure and Characterization of a Covalent Inhibitor of Src Kinase
D Gurbani, G Du, NJ Henning, S Rao, AK Bera, T Zhang, NS Gray, KD Westover |
Frontiers in Molecular Biosciences | 2020 |
Characterizing heterogeneity of non‐small cell lung tumour microenvironment to identify signature prognostic genes
K Mi, F Chen, Z Qian, J Chen, D Lv, C Zhang, Y Xu, H Wang, Y Zhang, Y Jiang, D Shang |
Journal of Cellular and Molecular Medicine | 2020 |
Conditional cell reprogramming for modeling host‐virus interactions and human viral diseases
X Liu, AM Mondal |
Journal of Medical Virology | 2020 |
Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
Z He, F Gong, J Liao, Q Wang, Y Su, C Chen, J Lin, R Lin |
Translational cancer research | 2020 |
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
BC Creelan, JE Gray, T Tanvetyanon, AA Chiappori, T Yoshida, MJ Schell, SJ Antonia, EB Haura |
British Journal of Cancer | 2019 |
MicroRNA in Lung Cancer Metastasis
SG Wu, TH Chang, YN Liu, JY Shih |
Cancers | 2019 |
Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs
M Farhan, A Malik, M Ullah, S Afaq, M Faisal, A Farooqi, B Biersack, R Schobert, A Ahmad |
International journal of molecular sciences | 2019 |
Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
SR, Melchior, Urbanska, Jakobsen, Stricker, Grauslund, Sørensen |
Cancers | 2019 |
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
PC, Krawczyk, Dakic, Simic, Yuan, Blancato, Wang, Hubbard, Zheng, Dan, Strome, Cullen, Davidson, Deeken, Choudhury, Ahn, Agarwal, Zhou, Schlegel, Furth, Pan, Liu |
Cells | 2019 |
Circular RNA circ‐CMPK1 contributes to cell proliferation of non‐small cell lung cancer by elevating cyclin D1 via sponging miR‐302e
D Cui, R Qian, Y Li |
Molecular Genetics & Genomic Medicine | 2019 |
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
S Rayego-Mateos, R Rodrigues-Diez, JL Morgado-Pascual, F Valentijn, JM Valdivielso, R Goldschmeding, M Ruiz-Ortega |
Mediators of Inflammation | 2018 |
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
Y Pan, L Jiao, C Lin, C Lu, L Li, H Chen, Y Wang, Y He |
Biologics : targets & therapy | 2018 |
Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors: 3T3+Y for NSCLC cell culture
RE Hynds, AB Aissa, KH Gowers, TB Watkins, L Bosshard-Carter, AJ Rowan, S Veeriah, GA Wilson, SA Quezada, C Swanton, SM Janes |
International Journal of Cancer | 2018 |
Role of miR‑23a/Zeb1 negative feedback loop in regulating epithelial‑mesenchymal transition and tumorigenicity of intraocular tumors
Y Wang, Y Luo, W Guan, H Zhao |
Oncology Letters | 2018 |
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer
KS Park, YW Moon, M Raffeld, DH Lee, Y Wang, G Giaccone |
Lung cancer (Amsterdam, Netherlands) | 2018 |
Collagen type I induces EGFR-TKI resistance in EGFR-mutated cancer cells by mTOR activation through Akt-independent pathway
S Yamazaki, Y Higuchi, M Ishibashi, H Hashimoto, M Yasunaga, Y Matsumura, K Tsuchihara, M Tsuboi, K Goto, A Ochiai, G Ishii |
Cancer Science | 2018 |
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
GM OKane, TA Barnes, NB Leighl |
Current Oncology | 2018 |
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
T Jiang, C Su, S Ren, F Cappuzzo, G Rocco, JD Palmer, N van Zandwijk, F Blackhall, X Le, NA Pennell, C Zhou |
Journal of Thoracic Disease | 2018 |
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
CL Sambrooks, M Baro, A Quijano, A Narayan, W Cui, P Greninger, R Egan, A Patel, CH Benes, WM Saltzman, JN Contessa |
Cancer research | 2018 |
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
PC Lee, YF Fang, H Yamaguchi, WJ Wang, TC Chen, X Hong, B Ke, W Xia, Y Wei, Z Zha, Y Wang, HP Kuo, CW Wang, CY Tu, CH Chen, WC Huang, SF Chiang, L Nie, J Hou, CT Chen, L Huo, WH Yang, R Deng, K Nakai, YH Hsu, SS Chang, TJ Chiu, J Tang, R Zhang, L Wang, B Fang, T Chen, KK Wong, JL Hsu, MC Hung |
Cancer Cell | 2018 |
[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer]
Li Yu, Sha Huang, Wang Lv, Zhehao He, Jian Hu |
Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2018 |
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer
A Legras, N Pécuchet, S Imbeaud, K Pallier, A Didelot, H Roussel, L Gibault, E Fabre, FL Pimpec-Barthes, P Laurent-Puig, H Blons |
Cancers | 2017 |
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
B Ricciuti, S Baglivo, L Paglialunga, AD Giglio, G Bellezza, R Chiari, L Crinò, G Metro |
Therapeutic advances in medical oncology | 2017 |
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
E Ichihara, D Westover, CB Meador, Y Yan, JA Bauer, P Lu, F Ye, A Kulick, E Stanchina, R McEwen, M Ladanyi, D Cross, W Pao, CM Lovly |
Cancer research | 2017 |
Clinical significance of cripto-1 expression in lung adenocarcinoma
H Zhang, B Zhang, L Gao, L Zhang, K Zhu, R Cheng, C Wang |
Oncotarget | 2017 |
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao |
OncoTargets and therapy | 2016 |
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
J Han, F Zhao, J Zhang, H Zhu, H Ma, X Li, L Peng, J Sun, Z Chen |
International journal of oncology | 2016 |
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
AN Phan, TN Hua, MK Kim, VT Vo, JW Choi, HW Kim, JK Rho, KW Kim, Y Jeong |
Oncotarget | 2016 |
Resisting Resistance: Targeted Therapies in Lung Cancer
JJ Lin, AT Shaw |
Trends in Cancer | 2016 |
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
VR Bhatt, SP DSouza, LM Smith, AM Cushman-Vokoun, V Noronha, V Verma, A Joshi, A Chougule, N Jambhekar, A Kessinger, A Marr, V Patil, SD Banavali, AK Ganti, K Prabhash |
Journal of Global Oncology | 2016 |
Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions
B Gao, C Huang, K Kernstine, V Pelekanou, Y Kluger, T Jiang, JR Peters-Hall, M Coquelin, L Girard, W Zhang, K Huffman, D Oliver, F Kinose, E Haura, JK Teer, U Rix, AT Le, DL Aisner, MV Garcia, RC Doebele, KR Covington, OA Hampton, HV Doddapaneni, JC Jayaseelan, J Hu, DA Wheeler, JW Shay, DL Rimm, A Gazdar, JD Minna |
Oncotarget | 2016 |
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Corte, M Fasano, F Ciardiello |
ESMO Open | 2016 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
L Huang, L Fu |
Acta Pharmaceutica Sinica B | 2015 |
Refining the treatment of NSCLC according to histological and molecular subtypes
A Thomas, SV Liu, DS Subramaniam, G Giaccone |
Nature Reviews Clinical Oncology | 2015 |
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
R Pagliarini, W Shao, WR Sellers |
EMBO reports | 2015 |
Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer
Y Chen, L Lu, B Feng, S Han, S Cui, X Chu, L Chen, R Wang |
Oncotarget | 2015 |
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra A, Mishra L, Li S |
Oncotarget | 2015 |
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities
Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F |
Oncotarget | 2015 |
Genetic modifiers of EGFR dependence in non-small cell lung cancer
T Sharifnia, V Rusu, F Piccioni, M Bagul, M Imielinski, AD Cherniack, CS Pedamallu, B Wong, FH Wilson, LA Garraway, D Altshuler, TR Golub, DE Root, A Subramanian, M Meyerson |
Proceedings of the National Academy of Sciences | 2014 |
MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use
SP Nana-Sinkam, CM Croce |
Genome biology | 2014 |
Cripto-1 as a novel therapeutic target for triple negative breast cancer
Castro NP, Fedorova-Abrams ND, Merchant AS, Rangel MC, Nagaoka T, Karasawa H, Klauzinska M, Hewitt SM, Biswas K, Sharan SK, Salomon DS |
Oncotarget | 2014 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |